Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Nick van Dijk(The Netherlands Cancer Institute), Alberto Gil-Jimenez(The Netherlands Cancer Institute), Karīna Siliņa(University of Zurich), Kees Hendricksen(The Netherlands Cancer Institute), Laura A. Smit(The Netherlands Cancer Institute), Jeantine M. de Feijter(The Netherlands Cancer Institute), Maurits L. van Montfoort(The Netherlands Cancer Institute), C. van Rooijen(The Netherlands Cancer Institute), Dennis Peters(The Netherlands Cancer Institute), Annegien Broeks(The Netherlands Cancer Institute), Henk G. van der Poel(University of Zurich), Annemarie Bruining(The Netherlands Cancer Institute), Yoni Lubeck(The Netherlands Cancer Institute), Karolina Sikorska(The Netherlands Cancer Institute), Thierry N. Boellaard(The Netherlands Cancer Institute), Pia Kvistborg(The Netherlands Cancer Institute), Daniël J. Vis(The Netherlands Cancer Institute), Erik Hooijberg(The Netherlands Cancer Institute), Ton N. Schumacher(The Netherlands Cancer Institute), Maries van den Broek(University of Zurich), Lodewyk F.A. Wessels(The Netherlands Cancer Institute), Christian U. Blank(The Netherlands Cancer Institute), Bas W. van Rhijn(University of Regensburg), Michiel S. van der Heijden(The Netherlands Cancer Institute)
Cited by 396Open Access